Burden, treatment use, and outcome of secondary mitral regurgitation across the spectrum of heart failure: observational cohort study

Philipp E. Bartko(Medical University of Vienna), Georg Goliasch(Medical University of Vienna), Georg Spinka(Medical University of Vienna), Cornelia Gabler(Medical University of Vienna), Maria Heitzinger(TU Wien), Noémi Pávó(Medical University of Vienna), Henrike Arfsten(Medical University of Vienna), Martin Hülsmann(Medical University of Vienna), Gregor Heitzinger(Medical University of Vienna), Guido Strunk(Complexity Science Hub), Martin Andreas(Medical University of Vienna), Christian Hengstenberg(Medical University of Vienna), Suriya Prausmüller(Medical University of Vienna), Julia Mascherbauer(University of Applied Sciences St Pölten)
BMJ
June 30, 2021
10.1136/bmj.n1421
Cited by 82

Related Papers

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study
|The Lancet|2022|310
A novel multistep mechanism for initial lymphangiogenesis in mouse embryos based on ultramicroscopy
|The EMBO Journal|2013|290
Right Ventricular-Pulmonary Arterial Coupling and Afterload Reserve in Patients Undergoing Transcatheter Tricuspid Valve Repair
|Journal of the American College of Cardiology|2022|261
Surgical Explantation After TAVR Failure
|JACC: Cardiovascular Interventions|2021|157
Conscious Sedation Versus General Anesthesia in Transcatheter Aortic Valve Replacement
|JACC: Cardiovascular Interventions|2018|144